Qube Research & Technologies (QRT)’s DiaMedica Therapeutics DMAC Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$73.7K	Buy	+10,881	New	+$86.2K	﹤0.01%	3115
2025 Q4	–	Sell	-39,549	Closed	-$272K	–	3755
2025 Q3	$272K	Buy	+39,549	New	+$215K	﹤0.01%	2876
2025 Q2	–	Sell	-36,929	Closed	-$140K	–	3631
2025 Q1	$140K	Sell	36,929 -57,840	-61%	-$331K	﹤0.01%	2946
2024 Q4	$515K	Buy	94,769 +42,680	+82%	+$201K	﹤0.01%	2462
2024 Q3	$218K	Buy	+52,089	New	+$192K	﹤0.01%	2547
2021 Q1	–	Sell	-18,785	Closed	-$190K	–	2011
2020 Q4	$190K	Sell	18,785 -12,449	-40%	-$68.1K	﹤0.01%	1546
2020 Q3	$132K	Buy	+31,234	New	+$165K	﹤0.01%	1463

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Qube Research & Technologies (QRT)'s DMAC Position: Q1 2026 in Review

Qube Research & Technologies (QRT) opened a new position in DiaMedica Therapeutics (DMAC) in Q1 2026: 10,881 shares worth $73.7K. The stake represents ﹤0.01% of the portfolio and ranks #3115 among its holdings. This is a return to the name: Qube Research & Technologies (QRT) previously reported a position in DMAC as recently as Q3 2025.

Qube Research & Technologies (QRT) first reported a position in DMAC in Q3 2020 and has held it in 7 quarters since. The position peaked at $515K in Q4 2024. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

Qube Research & Technologies (QRT) held 10,881 shares of DiaMedica Therapeutics worth $73.7K as of Q1 2026.
DiaMedica Therapeutics was a new Qube Research & Technologies (QRT) position in Q1 2026.
DiaMedica Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #3115 holding.
Qube Research & Technologies (QRT) first reported a position in DiaMedica Therapeutics in Q3 2020 and has held it in 7 quarters since.
Qube Research & Technologies (QRT)'s DiaMedica Therapeutics position peaked at $515K in Q4 2024.
98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.